Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat and Bortezomib in Recurrent Glioblastoma Multiforme
NCT00641706Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2008
- Primary completion
- Jul 2010
- Modality
- Modified Peptides, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat, bortezomib in glioblastoma multiforme (GBM), sponsored by National Cancer Institute. Started Jul 2008; status: completed.
02
Drugs
vorinostatbortezomib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00641706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00641706.